Low Testosterone After 50: When It Is Hypogonadism—and When It Is Not

A 54-year-old man presents with fatigue. An afternoon blood test reports low testosterone. That is not yet hypogonadism, and it does not make testosterone the automatic next step.

Low testosterone in men is diagnosed when compatible symptoms or signs coincide with unequivocally low concentrations measured reliably on at least two separate mornings. The cause then matters. Poor sleep, recent illness, obesity, sleep apnoea, low energy availability and several medicines can change both the result and the decision.

Testosterone replacement therapy (TRT) can relieve selected symptoms in appropriately diagnosed men. It is not an anti-ageing treatment, does not replace an aetiological work-up and has not been shown to extend life. The useful question is not “How do I raise my number?” but “Is deficiency confirmed, why is it happening and which outcome are we trying to improve?”

Low T symptoms: what is suggestive and what overlaps

Persistently reduced sexual desire, fewer spontaneous erections and certain reproductive changes are relatively more specific. Infertility, small testes, gynaecomastia, loss of body hair, unexplained anaemia or low bone mineral density can also contribute to the pattern. History, examination and timing matter.

Fatigue, low mood, disrupted sleep, more body fat, less muscle or difficulty concentrating are genuine but nonspecific. Depression, hypothyroidism, anaemia, diabetes, pain, stress, alcohol, medicines and sleep problems or apnoea can look similar. Treating a number before organising those possibilities may delay the right answer.

“Andropause” is a misleading analogy: there is no abrupt, universal hormonal transition equivalent to menopause. In 2026, the Endocrine Society noted that labels such as “age-related,” “late-onset” and “functional” hypogonadism may blur the line between treatable disease and usual ageing. It also found insufficient evidence for population screening of asymptomatic men.

How male hypogonadism is confirmed

1. Establish an indication: document symptoms, onset, sexual and reproductive function, medicines, alcohol, sleep, weight, recent illness and goals.
2. Repeat total testosterone: two fasting samples on separate mornings with a reliable assay while the patient is at baseline health. Use the same laboratory and method when possible.
3. Interpret the method, not only the flag: several guidelines use values near 300 ng/dL (10.4 nmol/L) or 12 nmol/L as support. Multiply ng/dL by 0.0347 to convert to nmol/L. The assay, laboratory range and clinical picture still matter.
4. Add SHBG and free testosterone when they change interpretation: if total testosterone is borderline or SHBG may be altered. Free T is calculated from total T, SHBG and albumin or measured with a reference method; not every direct assay is reliable.
5. Locate the origin: raised LH/FSH suggests a testicular cause; low or inappropriately normal levels suggest hypothalamic/pituitary disease or functional suppression. Prolactin, iron, other pituitary hormones, semen analysis or imaging are directed by the pattern, not ordered as a universal panel.
6. Review treatable contributors: opioids and glucocorticoids, obesity, sleep apnoea, systemic illness, low energy availability, overtraining and androgen use can alter the axis.

Obesity needs particular care because reduced SHBG can lower total testosterone while free testosterone remains preserved. Spanish GIRO guidance and the 2026 Endocrine Society statement place weight loss first when hypogonadism is associated with overweight or obesity and no other cause is identified. This is neither blame nor a promise of normalisation; it is treatment of a potentially reversible contributor with benefits of its own.

Finding	Next check	What may change
Fatigue + one low afternoon result	History, sleep, medicines and two fasting morning samples	May remove a false alarm before labelling or treating
Borderline total T with obesity or suspected SHBG change	SHBG, albumin and reliable calculated free T	Separates low total T driven by SHBG from more consistent deficiency
Low T + raised LH/FSH	Testicular assessment and acquired/genetic causes guided by history	Supports primary hypogonadism and cause-directed care
Low T + low/normal LH/FSH	Prolactin, medicines, obesity, systemic disease and pituitary work-up where indicated	May identify central disease or a reversible cause
Desire for future children	Reproductive history and semen analysis/specialist input if indicated	Avoids exogenous TRT and opens cause-directed alternatives
Symptoms + two low values + irreversible cause	Benefits, contraindications, preference, cost and monitoring plan	Supports a shared decision about physiological replacement

What TRT may improve—and the size of the effect

The most consistent evidence concerns sexual function in men with symptoms and confirmed low testosterone. The meta-analysis used by the Endocrine Society guideline found small improvements versus placebo: sexual desire SMD 0.17, erectile function 0.16 and sexual activity 0.23; an SMD near 0.2 is considered small.

In the TRAVERSE Sexual Function Study, 1,161 men aged 45–80 with low libido, two values below 300 ng/dL and cardiovascular disease or risk received 1.62% gel or placebo. Doses were adjusted to maintain 350–750 ng/dL and haematocrit below 54%: that is the trial protocol, not an individual dosing recommendation. The between-group difference on the sexual-activity diary was 0.49 at 6 months and 0.47 at 12 months; desire and hypogonadal symptoms improved, but erectile function did not.

TRT may increase lean mass, correct some otherwise unexplained anaemia and increase bone density in selected men. Those markers do not guarantee strength, independence or fewer fractures. If function is the goal, measure and train it directly; our sarcopenia and strength guide explains the distinction. For bone and body composition, the DEXA guide separates density, lean mass and clinical outcomes.

Goal	What the evidence shows	Decision limit
Libido and sexual activity	Small average improvement in symptomatic men with low levels	Not everyone responds; relationships, medicines and mental health still matter
Erectile dysfunction	Small meta-analytic effect; no benefit over placebo in the TRAVERSE substudy	Vascular, neurological, medication and psychological causes need assessment
Energy, cognition and strength	No consistent benefit supporting TRT as an “optimiser”	Investigate and treat specific causes
Lean mass or bone density	May increase in selected populations	A better marker is not the same as fewer falls or fractures
Longevity or cardiovascular prevention	Not demonstrated	Cardiovascular noninferiority is not cardioprotection

TRAVERSE: what is reassuring and what it cannot establish

TRAVERSE randomised 5,246 men aged 45–80 with symptoms, two fasting morning testosterone values below 300 ng/dL and established or high cardiovascular risk. Over a mean 33 months, cardiovascular death, myocardial infarction or stroke occurred in 7.0% with testosterone and 7.3% with placebo (HR 0.96; 95% CI 0.78–1.17), meeting the prespecified noninferiority criterion.

This does not establish lifetime safety, cardiovascular benefit or applicability to healthy eugonadal men. Atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and pulmonary embolism were more frequent with testosterone. In 2025, the FDA removed boxed-warning language about major adverse cardiovascular outcomes, retained the limitation for low testosterone attributed only to ageing and added a class-wide warning about increased blood pressure.

The fracture substudy did not show bone protection. Over a median 3.19 years, clinical fractures occurred in 3.50% with testosterone and 2.46% with placebo (HR 1.43; 95% CI 1.04–1.97). This is a safety signal requiring explanation and further study; it does not establish the mechanism of each fracture.

Adjudicated prostate events were infrequent and similar, but TRAVERSE excluded men at high prostate risk and prostate cancer develops slowly. The result is not a long-term guarantee. Baseline assessment and individual monitoring remain necessary.

TRT and fertility: the conversation that comes first

Exogenous testosterone suppresses LH and FSH, lowers intratesticular testosterone and can markedly impair spermatogenesis. Recovery after withdrawal may take months and has no guaranteed timetable. Desire for children, contraception, previous anabolic-steroid use and testicular health belong before prescribing.

A man with central hypogonadism who seeks fertility may need cause-directed treatment or specialist stimulation of the axis, not conventional TRT. Buying testosterone or “boosters” online bypasses that decision and adds uncertainty about composition, dose and interactions.

Before starting: contraindications and formulation choice

Guidelines advise against starting TRT in men seeking fertility soon, with active prostate or breast cancer, raised haematocrit, a prostate nodule or PSA requiring urological assessment, untreated severe obstructive sleep apnoea, severe urinary symptoms, uncontrolled heart failure, thrombophilia or a recent myocardial infarction or stroke. Individual risk needs clinical interpretation; this is not a self-screening checklist.

Gels, injections, patches and oral preparations are not interchangeable. Peaks and troughs, skin transfer, frequency, cost, reversibility, erythrocytosis and blood-pressure effects differ. Dosing is product-, assay-, symptom- and safety-specific; there is no universal “optimisation” regimen.

A decision and monitoring protocol

1. Before: document the target symptom, two reliable values and cause; ask about fertility; measure haematocrit and blood pressure, and assess cardiovascular, sleep-apnoea and prostate risk as appropriate.
2. Decide: compare cause-directed care, observation and TRT. Agree on an observable goal—such as sexual desire—and what treatment is not expected to fix.
3. Choose the formulation: based on preference, adjustability, comorbidity, transfer risk, access and cost. Prescribing is medical and individual.
4. Review early: check tolerance, correct use, blood pressure and adverse effects. The EAU recommends testosterone and haematocrit at 3, 6 and 12 months and annually thereafter; review more often with high erythrocytosis risk.
5. Apply safety limits: haematocrit above 54% requires adjustment or withdrawal and clinical management. PSA, urinary symptoms and prostate risk follow the agreed plan.
6. Use an exit rule: if levels correct but the target outcome does not improve within the agreed timeframe—or harms emerge—reassess diagnosis, adherence and alternatives instead of escalating indefinitely.

This is the logic of a personalized health plan: one question, the minimum useful data, an action and a review rule. Preventive medicine still matters—blood pressure, smoking, lipids, glucose and activity—whether testosterone is normal or treated. No hormone replaces those foundations.

Red flags

During TRT, chest pain, sudden breathlessness, coughing blood, painful one-sided leg swelling, sudden weakness, speech disturbance or a prolonged painful erection need urgent care. A new severe headache with visual change, galactorrhoea, neurological symptoms or very low testosterone with a central pattern warrants prompt pituitary assessment. Blood in urine, urinary retention, markedly worse breathing at night or persistent symptoms should also be reviewed rather than waiting for an annual appointment.

Frequently asked questions

What level counts as low testosterone?

There is no universal number independent of assay and context. Several guidelines use around 300 ng/dL (10.4 nmol/L) or 12 nmol/L as support, but symptoms/signs and two consistently low morning values are required.

Which symptoms are most informative?

Persistently reduced sexual desire and fewer spontaneous erections are more suggestive than fatigue alone. Infertility, small testes, gynaecomastia, unexplained anaemia or low bone density add context but do not diagnose by themselves.

Why repeat the blood test in the morning?

Testosterone varies between days, is usually higher in the morning and may fall with food, poor sleep or acute illness. Two fasting morning samples reduce misdiagnosis.

When are free testosterone and SHBG useful?

When total testosterone is borderline or altered SHBG is likely. Free testosterone should be calculated or measured with a validated method; direct assays are not all accurate.

Does TRT improve energy, muscle and erections?

The clearest average signal is a small sexual benefit in confirmed hypogonadism. TRT did not improve erectile function by itself in TRAVERSE and has not reliably restored energy, cognition or strength or prevented fractures.

Can I use TRT if I want children?

Not conventional exogenous TRT: it may suppress sperm production. Discuss cause-directed options with endocrinology, urology or reproductive medicine before taking an androgen.

Does TRT cause heart attacks or prostate cancer?

TRAVERSE did not show more major cardiovascular events over the medium term in its selected population, and prostate events were low after high-risk exclusions. It does not establish universal or lifetime safety; blood pressure, haematocrit and prostate risk still need follow-up.

Which tests are needed during treatment?

Before: cause, fertility, haematocrit, blood pressure, cardiovascular risk, sleep apnoea and prostate assessment where appropriate. During: symptoms, level, haematocrit, blood pressure and prostate surveillance; EAU guidance uses 3, 6 and 12 months, then annually for testosterone and haematocrit.

Sources

1. Endocrine Society. Testosterone therapy in men with hypogonadism: diagnosis and treatment guideline. Clinical guideline.
2. Endocrine Society. Statement on testosterone replacement therapy, 16 July 2026. 2026 statement.
3. European Association of Urology. Male hypogonadism, 2026 guideline. EAU.
4. Spanish Society of Endocrinology and Nutrition. GIRO 2024, obesity and male hypogonadism. GIRO guideline.
5. Lincoff AM et al. Cardiovascular safety of testosterone-replacement therapy, TRAVERSE. NEJM 2023.
6. Pencina KM et al. Sexual function in the TRAVERSE substudy. JCEM 2024.
7. Snyder PJ et al. Testosterone treatment and fractures in TRAVERSE. NEJM 2024.
8. Bhasin S et al. Prostate safety events during testosterone replacement therapy. JAMA Network Open 2023.
9. U.S. Food and Drug Administration. Class-wide labelling changes for testosterone products. FDA 2025.

Method note: Spanish and English SERPs, guidelines and studies reviewed on 3 September 2026. Figures describe specific populations and protocols and are not an individual recommendation. This page will be reviewed if guidance changes or new long-term safety evidence emerges.

If symptoms and results do not line up, you can request an assessment with the Progevita team to organise measurement, cause and options. The conclusion may be to treat another factor, observe, refer or consider TRT; assessment does not presume a prescription.